Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details about the current or expected order book value. However, it mentions that the U.S. Creative Development Centre secured its first customer order, with execution expected from Q4 this year to Q1 next year. European business showed 3% YoY growth in euro terms this quarter, indicating healthy demand. The company is seeing green shoots and new business opportunities in the U.S., Europe, U.K., Middle East, and Southeast Asia. There is some softness in demand in India post-GST changes, but the company expects sales momentum to recover shortly. Customer

Any current/future new fundraising through debt or equity?

The company anticipates a near-term increase in debt levels aligned with strategic initiatives and capacity expansion plans. Debt is expected to remain range-bound around the current gross debt level of approximately Rs. 800 crore, with a potential variation of +/- Rs. 20-30 crore in the immediate 3 to 6 months. No explicit mention of new equity fundraising was made during the transcript. Focus will be on capital discipline, tighter capital allocation, and improving working capital efficiency to manage balance sheet strength. Investments are ongoing, with committed capex in Europe (EUR 2-3 mil

Any current/future capex/capital investment/strategic investment?

Europe: Committed EUR 7-8 million capex, mostly done; expects another EUR 2-3 million outflow in next 6-12 months. New factory expected operational by Q4 FY26, expanding capacity 1.5x from current 90% utilization. India: Capex of Rs. 70-80 crore over next 12-18 months focused on rebuilding facilities (Vashivali and Vanavate) post-fire and new expansions; adding 9,000 tons capacity in Q1 FY27 and further 15,000 tons later. U.S.: Investment primarily opex for leased manufacturing and creative development centres (~$1.5-2 million invested); expecting $2-2.5 million business by end of next yea

Future growth expectations in sales/revenue/volumes?

The company targets a 12% year-on-year CAGR growth with FY '24-'25 as the base year. Additional capacity in Southeast Asia (3,600 tons) is expected to add 5-7 million in turnover sales. European capacity catering to €50 million is about 90% utilized; plans to increase capacity by 1.5x soon to support aggressive growth in Europe. India has current capacity of ~20,000 tons with expansions adding 9,000 tons in Q1 next year and another 15,000 tons thereafter, indicating strong growth headroom. Strong double-digit growth is seen in Middle East, Africa, Central Asia, and Southeast Asia marke

Future growth expectations in earnings/operating earnings/profits/EPS?

Flavours EBIT margins expected to remain steady at 20%-22% through FY27-FY28. Fragrances EBIT margins projected to improve from current ~8% to 13%-14% over 2-4 years, especially as outside India operations ramp up. Blended Fragrances segment EBIT expected around 17%-18%; EBITDA margins are 14%-17%, with EBIT margins 2%-3% higher. Overall business EBITDA expected to rise from current 13% to about 17% in next 2 years. The company targets a 12% year-on-year revenue CAGR from FY24-25 onwards. Return Ratios (ROE/ROCE) currently in single digits (~6%-8%), expected to improve to mid-teens (around 14%

IN US

Sale is live|00:00:00left today

S H Kelkar & Company LtdQ4 FY27Chemicals & Petrochemicals

S H Kelkar & Company Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹135P/E: 38.1Market Cap: ₹1.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a 12% year-on-year CAGR growth with FY '24-'25 as the base year.
→Additional capacity in Southeast Asia (3,600 tons) is expected to add 5-7 million in turnover sales.
→European capacity catering to €50 million is about 90% utilized; plans to increase capacity by 1.5x soon to support aggressive growth in Europe.
→India has current capacity of ~20,000 tons with expansions adding 9,000 tons in Q1 next year and another 15,000 tons thereafter, indicating strong growth headroom.
→Strong double-digit growth is seen in Middle East, Africa, Central Asia, and Southeast Asia markets.
→U.S. market initiatives are beginning to generate orders, with business expected to grow from Q4 this year and into FY '29.
→Growth drivers include new CDCs, operational expansions, and leveraging innovation in emerging markets and smaller clients.
→The company expects to reach double-digit return ratios (~14%) by FY '29, indicating profitable/top-line growth.

Margin guidance

→Flavours EBIT margins expected to remain steady at 20%-22% through FY27-FY28.
→Fragrances EBIT margins projected to improve from current ~8% to 13%-14% over 2-4 years, especially as outside India operations ramp up.
→Blended Fragrances segment EBIT expected around 17%-18%; EBITDA margins are 14%-17%, with EBIT margins 2%-3% higher.
→Overall business EBITDA expected to rise from current 13% to about 17% in next 2 years.
→The company targets a 12% year-on-year revenue CAGR from FY24-25 onwards.
→Return Ratios (ROE/ROCE) currently in single digits (~6%-8%), expected to improve to mid-teens (around 14%) by FY28-FY29.
→New investments and capacity expansions are expected to break-even and contribute positively in 2-3 years.
→Operating leverage and gross margin improvements will drive profitability gains.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company anticipates a near-term increase in debt levels aligned with strategic initiatives and capacity expansion plans.
→Debt is expected to remain range-bound around the current gross debt level of approximately Rs. 800 crore, with a potential variation of +/- Rs. 20-30 crore in the immediate 3 to 6 months.
→No explicit mention of new equity fundraising was made during the transcript.
→Focus will be on capital discipline, tighter capital allocation, and improving working capital efficiency to manage balance sheet strength.
→Investments are ongoing, with committed capex in Europe (EUR 2-3 million in the next 6-12 months) and India (Rs. 70-80 crore in the next 12-18 months), partly funded through debt.
→Management is working on detailed plans for cash flow and debt management, with expectations of positive cash flow from new investments starting in 2-3 years.

Order book

→The transcript does not provide explicit details about the current or expected order book value.
→However, it mentions that the U.S. Creative Development Centre secured its first customer order, with execution expected from Q4 this year to Q1 next year.
→European business showed 3% YoY growth in euro terms this quarter, indicating healthy demand.
→The company is seeing green shoots and new business opportunities in the U.S., Europe, U.K., Middle East, and Southeast Asia.
→There is some softness in demand in India post-GST changes, but the company expects sales momentum to recover shortly.
→Customer interactions globally are encouraging, especially with smaller brands and e-commerce businesses driving growth.
→Overall, the business pipeline appears promising with a phased build-up over the next 2-3 years as new facilities and markets scale.

Capex plans

Yes

→Europe: Committed EUR 7-8 million capex, mostly done; expects another EUR 2-3 million outflow in next 6-12 months. New factory expected operational by Q4 FY26, expanding capacity 1.5x from current 90% utilization.
→India: Capex of Rs. 70-80 crore over next 12-18 months focused on rebuilding facilities (Vashivali and Vanavate) post-fire and new expansions; adding 9,000 tons capacity in Q1 FY27 and further 15,000 tons later.
→U.S.: Investment primarily opex for leased manufacturing and creative development centres (~$1.5-2 million invested); expecting $2-2.5 million business by end of next year. Minimal capex as manufacturing is operational lease-based.
→Strategic focus on organic growth in U.S., Europe, and Southeast Asia with enhanced Creative Development Centres (CDCs) to generate new business.
→Overall capex timeline: majority expected to be deployed within 12 to 18 months.

How does S H Kelkar & Company Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1S H Kelkar & Company Ltd

Rev 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like S H Kelkar & Company Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio